APYX Q1 2026: Aon Drives 36% Surgical Aesthetics Surge, Sets Stage for Power Lipo Expansion
Aon’s rapid adoption propelled a 32% revenue jump as APYX leverages GLP-1 tailwinds and international momentum. Management’s disciplined operating model and targeted innovation are strengthening the company’s position in surgical aesthetics, with power liposuction clearance poised to unlock new market segments. Upward guidance revision signals confidence in continued expansion, but tariff exposure and OEM contraction remain watchpoints.
Summary
- Aon Adoption Expands Surgical Suite Reach: Early-stage rollout and label expansion position Aon as a platform play in body contouring.
- International and Consumables Fuel Growth: South Korea and global handpiece demand offset OEM softness and bolster revenue mix.
- Power Lipo Clearance to Broaden TAM: Regulatory milestone expected to accelerate penetration among new surgeon segments.
Business Overview
APYX Medical develops and commercializes energy-based medical devices, specializing in surgical aesthetics, body contouring procedures using proprietary technology, and OEM (original equipment manufacturer, contract manufacturing for third parties). The company’s flagship products, Renuvion and Aon, are platforms for minimally invasive skin tightening and fat removal. Revenue is primarily generated from device sales, consumables (single-use handpieces), and service, with surgical aesthetics representing the majority of the business and OEM providing a smaller, declining contribution.
Performance Analysis
APYX delivered a 32% year-over-year revenue increase to $12.5 million, led by a 36% jump in surgical aesthetics to $10.7 million, underscoring the rapid uptake of Aon since its full launch in late 2025. This growth was attributed to robust U.S. demand for body contouring, expanding international sales—especially in South Korea—and increased consumables pull-through, reflecting both new account wins and deeper penetration in existing customer bases.
Gross margin improved to 63.5%, up from 60.1% last year, as the mix shifted further toward higher-margin surgical aesthetics. Operating expenses remained tightly controlled, essentially flat year-over-year, enabling a significant reduction in net loss and adjusted EBITDA loss. The OEM segment grew modestly this quarter but is expected to decline over time as focus intensifies on the core surgical aesthetics franchise. Notably, international revenue rose 63%, now accounting for more than a third of total sales, highlighting successful regulatory and commercial execution abroad.
- Surgical Aesthetics Outpaces OEM: Segment now comprises the vast majority of revenue, with OEM’s relevance diminishing as strategic focus narrows.
- Consumables and International Outperformance: Handpiece sales and new generator placements in Asia offset domestic generator softness.
- Operating Leverage Materializes: Flat expenses and improved margin structure drive steeper loss reduction than topline growth alone would suggest.
Cash burn remains low, with $31.1 million cash on hand projected to fund operations through 2027. The upwardly revised full-year guidance reflects management’s confidence in sustained demand and operational discipline.
Executive Commentary
"Through the launch of Aon, we have expanded our customer relationships beyond individual technologies to a more comprehensive presence in the surgical suite, supporting a wider range of procedures and workflows."
Charlie Goodwin, President and Chief Executive Officer
"We believe, based on our projections, including the uptake of the Aon platform, working capital management, and our strict cost controls, we'll yield cash through 2027."
Matt Hill, Chief Financial Officer
Strategic Positioning
1. Aon Platform as Surgical Suite Anchor
Aon’s integration of multiple body contouring modalities positions it as a platform rather than a point solution, enabling workflow consolidation and broader procedural reach. This approach is expanding APYX’s addressable market within surgical centers and driving upgrades from the existing Renuvion base.
2. Power Liposuction Label Expansion
The anticipated FDA 510(k) clearance for power-assisted liposuction will allow Aon to serve surgeons who exclusively use this modality, unlocking a significant segment previously inaccessible. Management is staging a limited launch to optimize training and customer experience before full-scale rollout, mirroring the disciplined approach taken with the initial Aon launch.
3. International Commercialization Momentum
Recent regulatory wins in Asia, particularly South Korea, have catalyzed new generator and consumable sales. APYX is actively pursuing Aon registration in major global markets, including Europe, Latin America, and the Middle East, aiming to replicate U.S. success and diversify revenue streams.
4. Lean Operating Model and Reinvestment
Cost discipline enacted last year is yielding sustained operating leverage, freeing capital for targeted growth investments—especially in commercial expansion and product development. This model is designed to balance profitability with innovation as the business scales.
5. GLP-1 Tailwind and Consumer Demand
Surging adoption of GLP-1 weight loss drugs is increasing the pool of patients seeking solutions for loose skin, directly benefiting demand for APYX’s body contouring technologies. Management is tracking consumer trends and surgeon feedback, reinforcing the company’s alignment with evolving patient needs.
Key Considerations
APYX’s strategic execution this quarter underscores a pivotal transition from product-centric sales to a platform and procedural ecosystem model. The company’s ability to capitalize on both technology differentiation and secular demand drivers sets the stage for multi-year growth, but requires flawless execution on international expansion and regulatory milestones.
Key Considerations:
- GLP-1 Patient Surge Drives Demand: Rapid weight loss from GLP-1 drugs is funneling new patients into body contouring procedures, expanding the underlying market.
- Label Expansion as Adoption Catalyst: Power lipo clearance is a gating factor for unlocking new surgeon segments and accelerating Aon’s upgrade cycle.
- OEM Revenue Decline Structural: As surgical aesthetics becomes dominant, OEM’s contraction will reduce diversification, increasing exposure to core market trends.
- Tariff Management Remains Critical: Tariffs are factored into guidance, but ongoing vigilance and dual manufacturing sites are required to mitigate cost volatility.
- International Execution Complexity: Success hinges on navigating regulatory timelines and tailoring commercial strategies to diverse global markets.
Risks
Tariff exposure and geographic mix shifts could pressure gross margins, especially if international sales outpace domestic growth or if trade policies change unexpectedly. OEM revenue decline reduces business diversification, making APYX more sensitive to surgical aesthetics market swings. Regulatory delays or missteps in international approvals could stall expansion, and competitive innovation remains a persistent threat in the device landscape. Finally, macroeconomic or geopolitical disruptions could dampen elective procedure demand, despite current resilience.
Forward Outlook
For Q2 2026, APYX expects continued momentum in surgical aesthetics, with incremental contributions from international markets and consumables. For full-year 2026, management raised guidance:
- Total revenue: $59 million to $60 million (previously $57.5 million to $58.5 million)
- Surgical aesthetics: $54 million to $55 million (previously $53 million to $54 million)
- OEM: approximately $5 million (previously $4.5 million)
- Gross margin: 62% to 63%
- Operating expenses: not to exceed $45 million
Management cited Aon adoption, power lipo clearance, and international expansion as key drivers, while reiterating cost controls and cash runway through 2027.
- Power lipo FDA clearance expected this quarter to expand addressable market
- Ongoing international regulatory filings to extend Aon’s global footprint
Takeaways
APYX is leveraging product innovation and secular demand trends to drive above-market growth, but must sustain disciplined execution as the platform scales globally and competitive intensity rises.
- Aon’s Platform Model Unlocks Multi-Procedure Value: The shift from single-device sales to integrated procedural solutions is deepening customer relationships and broadening market access.
- Sustained Margin Expansion Relies on Mix and Tariff Mitigation: Geographic and product mix, along with cost controls, will determine profitability as international sales ramp.
- Investors Should Watch Power Lipo Uptake and International Approvals: These milestones are critical for sustaining growth and validating the platform’s global relevance in 2026 and beyond.
Conclusion
APYX’s Q1 2026 results validate its transformation into a surgical aesthetics platform leader, with Aon’s early traction, disciplined cost structure, and GLP-1-driven demand positioning the company for continued expansion. Execution on upcoming regulatory and geographic milestones will determine the durability of this growth trajectory.
Industry Read-Through
APYX’s performance and commentary highlight accelerating demand for body contouring solutions as GLP-1 adoption reshapes the aesthetics landscape. Device makers with integrated platforms and procedural versatility are best positioned to capture share as patient needs evolve. The success of limited commercial launches and disciplined operating models offers a blueprint for medtech innovators seeking to balance growth and profitability. International regulatory agility and tariff mitigation are increasingly strategic, as global expansion becomes a primary lever for medtech growth. Competitors should note the rising importance of consumables pull-through and the need to address both new and upgrade customer cohorts in a rapidly shifting market.